Advertisement

Topics

Neuromod Devices Limited Company Profile

04:35 EST 18th January 2019 | BioPortfolio

Neuromod, headquartered in the Digital Hub, Dublin, Ireland, is an emerging medical technology company, specialising in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The company was founded in 2010, by Dr. Ross O’Neill, as a spin-out from Maynooth University. The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod is conducting extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder for which no standard of care has yet been established. Tinnitus affects between 10 and 15% of the global population, and the lives of at least 1 in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears.


News Articles [621 Associated News Articles listed on BioPortfolio]

Neuromod Appoints Leading Tinnitus Expert Professor Richard S. Tyler, PhD to its Clinical Advisory Board

Neuromod Devices Limited (“Neuromod”), an Irish medical technology company specialising in non-invasive neuromodulation technologies, is delighted to announce that Professor R...

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ he...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously annou...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million ...

Genetic Technologies Limited Announces New Biomedical Blockchain Joint Venture

MELBOURNE, Australia, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), via its subsidiary Gene Ventures Pty Ltd, is pleased to announce that i...

Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference

JERSEY, Channel Islands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop,...

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an ...

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation...

PubMed Articles [721 Associated PubMed Articles listed on BioPortfolio]

Fabrication of Electrochemical-Based Bioelectronic Device and Biosensor Composed of Biomaterial-Nanomaterial Hybrid.

The field of bioelectronics has paved the way for the development of biochips, biomedical devices, biosensors and biocomputation devices. Various biosensors and biomedical devices have been developed ...

Assessment of metallic patient support devices and other items at 7-Tesla: Findings applied to 46 additional devices.

Recently, the first 7-Tesla MR system was approved for clinical use in Europe and the United States. Unfortunately, few metallic objects have undergone testing in association with this high-field-stre...

Transcatheter tricuspid valve intervention: a practical algorithm for patient selection.

Worldwide experience in transcatheter tricuspid valve intervention is increasing as more options become available for the treatment of severe tricuspid regurgitation. These devices can be categorized ...

The regulatory ancestral network of surgical meshes.

All surgical meshes entering the U.S. market have been cleared for clinical use by the 510(k) process of the Food and Drug Administration (FDA), in which devices simply require proof of "substantial e...

Patch Pumps for Insulin.

Newly developed patch pumps are starting to occupy a noticeable fraction of the insulin delivery market. New entrants, using novel technologies, promise accurate, flexible insulin delivery at lower co...

Clinical Trials [1131 Associated Clinical Trials listed on BioPortfolio]

Adjustment Exploratory Protocols and Functional Evaluation of New Non Invasive Devices in Healthy Volunteers

Parameters, sequences or paradigms optimisation in view of data quality and relevancy improvement.

Transvenous Lead Removal Post-Market Clinical Study

This prospective, multicenter, post-market clinical study was designed to evaluate the outcomes of lead extraction of cardiovascular implantable electronic devices (CIED) using Cook cathet...

Glottic View Using Supraglottic Devices in Pediatric Patients

Endotracheal intubation is the gold standard for securing the airway. However, while managing patients with difficult airways, various supraglottic devices have been used as rescue airway ...

A Comparison of Accelerometers for Measuring Daily Activity in Sarcoid

This cross-over study of 12 patients with sarcoidosis will look at two different widely-used accelerometer devices. These devices are wrist worn and similar in size to a wrist-watch. They ...

Participatory Organizational Intervention for Improved Use of Assistive Devices for Patient Handling

Epidemiological studies have shown that patient transfer is a risk factor for back pain, back injuries and long term sickness absence, whereas consistent use of assistive devices during pa...

Companies [1121 Associated Companies listed on BioPortfolio]

Neuromod Devices Limited

Neuromod, headquartered in the Digital Hub, Dublin, Ireland, is an emerging medical technology company, specialising in the design and development of neuromodulation technologies ...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Neuromod

Toumaz Limited

Toumaz Limited is an AIM-listed group focused on opportunities in medical devices, healthcare IT and consumer electronics. Based on a portfolio of unique and world-leading silicon chip technologies,...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

More Information about "Neuromod Devices Limited" on BioPortfolio

We have published hundreds of Neuromod Devices Limited news stories on BioPortfolio along with dozens of Neuromod Devices Limited Clinical Trials and PubMed Articles about Neuromod Devices Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neuromod Devices Limited Companies in our database. You can also find out about relevant Neuromod Devices Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record